Business Description
PMV Pharmaceuticals is a US-based drug development company focused on treating cancers driven by a specific genetic defect known as the p53 mutation. Its lead drug candidate, rezatapopt, is currently being tested in Phase 2 clinical trials across multiple cancer types that share this mutation, regardless of where in the body the cancer originates. The company was founded in 2013 and operates out of Princeton, New Jersey.
